key Findings of the EPCORE FL-1 Trial (Epcoritamab + R & Lenalidomide) for Relapsed/Refractory follicular Lymphoma:
The EPCORE FL-1 trial, a phase 3 randomized study, demonstrated significant benefits of adding epcoritamab to the standard treatment of rituximab and lenalidomide (R) for patients with relapsed or refractory follicular lymphoma who had previously received at least one systemic therapy (including an anti-CD20 agent + chemotherapy).HereS a summary of the key findings:
* High Overall Response Rate: The combination of epcoritamab + R achieved a 95% overall response rate, significantly higher than the 79% seen with R alone.
* Improved Progression-Free Survival: The risk of disease progression or death was reduced by 79% with the addition of epcoritamab. Progression-free survival also favored the combination.
* Durable Responses: Complete response rates and duration of response were substantially higher with epcoritamab + R. The median duration of response has not yet been reached, indicating long-lasting benefit.
* Manageable Safety Profile: while some cytokine release syndrome (CRS) was observed, it was typically low-grade (Grade 1 or 2) and manageable with standard mitigation strategies. No new safety signals were identified.
* Novel Mechanism of Action: Epcoritamab is a CD3xCD20 bispecific T-cell engager that directly redirects a patient’s own T cells to kill lymphoma cells, offering a targeted, chemotherapy-free approach.
In essence, the trial showed that epcoritamab in combination with R significantly improves outcomes for patients with relapsed/refractory follicular lymphoma, offering a promising and perhaps durable treatment option with a manageable safety profile.
